Jaume Pons

Company: ALX Oncology

Job title: President & Chief Executive Officer

Seminars:

Evorpacept: a Phase 2 CD47 Blocker Uniquely Designed for Use in Combination Therapies to Safely Maximize Anti-Cancer Activity 11:30 am

• ALX Oncology’s lead product candidate, evorpacept, is a next-generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain • Evorpacept has demonstrated promising clinical responses and tolerability across a range of hematologic and solid malignancies in combination with targeted antibodies, pembrolizumab, and chemotherapy • ALX is currently…Read more

day: Day One Track B AM